NIOSH Skin Notation Profiles
Tetraethyl dithionopyrophosphate (TEDP)
This page intentionally left blank.
NIOSH Skin Notation (SK) Profile

Tetraethyl dithionopyrophosphate (TEDP)
[CAS No. 3689-24-5]

Naomi L. Hudson and G. Scott Dotson
Disclaimer

Mention of any company or product does not constitute endorsement by the National Institute for Occupational Safety and Health (NIOSH). In addition, citations to websites external to NIOSH do not constitute NIOSH endorsement of the sponsoring organizations or their programs or products. Furthermore, NIOSH is not responsible for the content of these websites.

Ordering Information

To receive this document or information about other occupational safety and health topics, contact NIOSH:

- Telephone: 1-800-CDC-INFO (1-800-232-4636)
- TTY: 1-888-232-6348
- E-mail: cdcinfo@cdc.gov

Or visit the NIOSH website: [www.cdc.gov/niosh](http://www.cdc.gov/niosh)

For a monthly update on news at NIOSH, subscribe to *NIOSH eNews* by visiting [www.cdc.gov/niosh/eNews](http://www.cdc.gov/niosh/eNews).

Suggested Citation


DHHS (NIOSH) Publication No. 2015-227

September 2015

**Safer • Healthier • People™**
Foreword

As the largest organ of the body, the skin performs multiple critical functions, such as serving as the primary barrier to the external environment. For this reason, the skin is often exposed to potentially hazardous agents, including chemicals, which may contribute to the onset of a spectrum of adverse health effects ranging from localized damage (such as irritant contact dermatitis and corrosion) to induction of immune-mediated responses (such as allergic contact dermatitis and pulmonary responses) or systemic toxicity (such as neurotoxicity and hepatotoxicity). Understanding the hazards related to skin contact with chemicals is a critical component of modern occupational safety and health programs.

In 2009, the National Institute for Occupational Safety and Health (NIOSH) published Current Intelligence Bulletin (CIB) 61: A Strategy for Assigning New NIOSH Skin Notations [NIOSH 2009-147]. This document provides the scientific rationale and framework for the assignment of multiple hazard-specific skin notations (SK) that clearly distinguish between the systemic effects, direct (localized) effects, and immune-mediated responses caused by skin contact with chemicals. The key step within assignment of the hazard-specific SK is the determination of the hazard potential of the substance, or its potential for causing adverse health effects as a result of skin exposure. This determination entails a health hazard identification process that involves use of the following:

- Scientific data on the physicochemical properties of a chemical
- Data on human exposures and health effects
- Empirical data from in vivo and in vitro laboratory testing
- Computational techniques, including predictive algorithms and mathematical models that describe a selected process (such as skin permeation) by means of analytical or numerical methods.

This Skin Notation Profile provides the SK assignments and supportive data for tetraethyl dithionopyrophosphate (TEDP). In particular, this document evaluates and summarizes the literature describing the hazard potential of the substance and its assessment according to the scientific rationale and framework outlined in CIB 61. In meeting this objective, this Skin Notation Profile intends to inform the audience—mostly occupational health practitioners, researchers, policy- and decision-makers, employers, and workers in potentially hazardous workplaces—so that improved risk-management practices may be developed to better protect workers from the risks of skin contact with the chemicals of interest.

John Howard, M.D.
Director, National Institute for Occupational Safety and Health
Centers for Disease Control and Prevention
This page intentionally left blank.
## Contents

- Foreword ................................................................. iii
- Abbreviations .......................................................... vi
- Glossary .................................................................. viii
- Acknowledgments ................................................... ix
- 1 Introduction ......................................................... 1
  - 1.1 General Substance Information .......................... 1
  - 1.2 Purpose ............................................................. 1
  - 1.3 Overview of SK Assignment .............................. 1
- 2 Systemic Toxicity from Skin Exposure (SK: SYS) .... 2
- 3 Direct Effects on Skin (SK: DIR) ............................. 3
- 4 Immune-mediated Responses (SK: SEN) .................. 3
- 5 Summary ............................................................... 3
- References .............................................................. 4
- Appendix: Calculation of the SI Ratio for TEDP .......... 6
  - Overview ............................................................... 6
  - Calculation ............................................................ 7
  - Appendix References ............................................. 7
Abbreviations

ACGIH  American Conference of Governmental Industrial Hygienists
Amu  atomic mass unit
ATSDR  Agency for Toxic Substances and Disease Registry
ChE  cholinesterase
CIB  Current Intelligence Bulletin
cm²  square centimeter(s)
cm/hr  centimeter(s) per hour
cm/s  centimeter(s) per second
DEREK  Deductive Estimation of Risk from Existing Knowledge
DIR  skin notation indicating the potential for direct effects to the skin following contact with a chemical
EC  European Commission
GHS  Globally Harmonized System for Classification and Labelling of Chemicals
GPMT  guinea pig maximization test
hr  hour(s)
IARC  International Agency for Research on Cancer
(IRR)  subnotation of SK: DIR indicating the potential for a chemical to be a skin irritant following exposure to the skin
$k_{aq}$  coefficient in the watery epidermal layer
$k_p$  skin permeation coefficient
$k_{pol}$  coefficient in the protein fraction of the stratum corneum
$k_{psc}$  permeation coefficient in the lipid fraction of the stratum corneum
LD₅₀  dose resulting in 50% mortality in the exposed population
LD₁₀  dermal lethal dose
LLNA  local lymph node assay
LOAEL  lowest-observed-adverse-effect level
log $K_{OW}$  base-10 logarithm of a substance’s octanol–water partition
$M$  molarity
$m^3$  cubic meter(s)
mg  milligram(s)
mg/cm²/hr  milligram(s) per square centimeter per hour
mg/kg  milligram(s) per kilogram body weight
mg/m³  milligram(s) per cubic meter
mL  milliliter(s)
mL/kg  milliliter(s) per kilogram body weight
MW  molecular weight
NIOSH  National Institute for Occupational Safety and Health
NOAEL  no-observed-adverse-effect level
NTP  National Toxicology Program
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>OEL</td>
<td>occupational exposure limit</td>
</tr>
<tr>
<td>OSHA</td>
<td>Occupational Safety and Health Administration</td>
</tr>
<tr>
<td>ppm</td>
<td>parts per million</td>
</tr>
<tr>
<td>REL</td>
<td>recommended exposure limit</td>
</tr>
<tr>
<td>RF</td>
<td>retention factor</td>
</tr>
<tr>
<td>SEN</td>
<td>skin notation indicating the potential for immune-mediated reactions following exposure of the skin</td>
</tr>
<tr>
<td>SI</td>
<td>ratio ratio of skin dose to inhalation dose</td>
</tr>
<tr>
<td>SK</td>
<td>skin notation</td>
</tr>
<tr>
<td>$S_w$</td>
<td>solubility in water</td>
</tr>
<tr>
<td>SYS</td>
<td>skin notation indicating the potential for systemic toxicity following exposure of the skin</td>
</tr>
<tr>
<td>TEDP</td>
<td>tetraethyl dithionopyrophosphate</td>
</tr>
<tr>
<td>US EPA</td>
<td>United States Environmental Protection Agency</td>
</tr>
<tr>
<td>µg</td>
<td>microgram(s)</td>
</tr>
<tr>
<td>µL</td>
<td>microliter(s)</td>
</tr>
<tr>
<td>µmol</td>
<td>micromole(s)</td>
</tr>
</tbody>
</table>
Glossary

**Absorption**—The transport of a chemical from the outer surface of the skin into both the skin and systemic circulation (including penetration, permeation, and resorption).

**Acute exposure**—Contact with a chemical that occurs once or for only a short period of time.

**Cancer**—Any one of a group of diseases that occur when cells in the body become abnormal and grow or multiply out of control.

**Contaminant**—A chemical that is (1) unintentionally present within a neat substance or mixture at a concentration less than 1.0% or (2) recognized as a potential carcinogen and present within a neat substance or mixture at a concentration less than 0.1%.

**Cutaneous (or percutaneous)**—Referring to the skin (or through the skin).

**Dermal**—Referring to the skin.

**Dermal contact**—Contact with (touching) the skin.

**Direct effects**—Localized, non-immune-mediated adverse health effects on the skin, including corrosion, primary irritation, changes in skin pigmentation, and reduction/disruption of the skin barrier integrity, occurring at or near the point of contact with chemicals.

**Immune-mediated responses**—Responses mediated by the immune system, including allergic responses.

**Sensitization**—A specific immune-mediated response that develops following exposure to a chemical, which, upon re-exposure, can lead to allergic contact dermatitis (ACD) or other immune-mediated diseases such as asthma, depending on the site and route of re-exposure.

**Substance**—A chemical.

**Systemic effects**—Systemic toxicity associated with skin absorption of chemicals after exposure of the skin.
Acknowledgments

This document was developed by the Education and Information Division (Paul Schulte, Ph.D., Director). G. Scott Dotson, Ph.D., was the project officer for this document, assisted in great part by Naomi Hudson, Dr.P.H., M.P.H., H. Fredrick Frasch, Ph.D., and Vic Johnson, Ph.D. The basis for this document was a report (Toxicology Excellence for Risk Assessment [TERA]) contracted by NIOSH and prepared by Bernard Gadagbui, Ph.D., and Andrew Maier, Ph.D.

For their contribution to the technical content and review of this document, special acknowledgment is given to the following NIOSH personnel:

**Denver Field Office**
Eric Esswein, M.Sc.

**Division of Applied Research and Technology**
Clayton B’Hymer, Ph.D.
John Snawder, Ph.D.
Mark Toraason, Ph.D.

**Division of Respiratory Disease Studies**
Gregory A. Day, Ph.D.
Aleksander Stefaniak, Ph.D.

**Division of Surveillance, Hazard Evaluations, and Field Studies**
Matt Dahm, M.Sc.
Todd Niemeier, M.Sc.
Aaron Sussell, Ph.D.
Loren Tapp, M.D.

**Education and Information Division**
Devin Baker, M.Ed.
Charles L. Geraci, Ph.D.
Thomas J. Lentz, Ph.D.
Richard Niemeier, Ph.D.
Ralph Zumwalde, M.Sc.

**Health Effects Laboratory Division**
Stacey Anderson, Ph.D.
Michael Luster, Ph.D.
Anna Shvedova, Ph.D.
Paul Siegel, Ph.D.
Berran Yucesoy, Ph.D.

**National Personal Protective Technology Laboratory**
Heinz Ahlers, J.D., M.Sc.
Angie Shepherd
For their contribution to the technical content and review of this document, special acknowledgment is given to the following CDC personnel:

Office of Surveillance, Epidemiology and Laboratory Services/Epidemiology and Analysis Program Office
Barbara Landreth, M.A.

In addition, special appreciation is expressed to the following individuals for serving as independent, external reviewers and providing comments that contributed to the development or improvement of this document:

John Herbold, D.V.M., Ph.D., M.P.H., San Antonio, TX
Shane Stephen Que Hee, M.Sc., Ph.D., University of California at Los Angeles, School of Public Health, Los Angeles, CA
G. Frank Gerberick, Ph.D., The Procter and Gamble Company, Cincinnati, OH
Dori Germolec, Ph.D., National Toxicology Program, National Institute for Environmental Health Sciences, Research Triangle, NC
Ben Hayes, M.D., Ph.D., Division of Dermatology, Vanderbilt School of Medicine, Nashville, TN
Jennifer Sahmel, M.Sc., CIH, ChemRisk, Boulder, CO
James Taylor, M.D., Industrial Dermatology, The Cleveland Clinic, Cleveland, OH
1 Introduction

1.1 General Substance Information

**Chemical:** Tetraethyl dithionopyrophosphate (TEDP)

**CAS No:** 3689-24-5

**Molecular weight** (*MW*): 322.3

**Molecular formula:** \( [(\text{CH}_3\text{CH}_2\text{O})_2\text{PS}]_2\text{O} \)

**Structural formula:**

![Structural formula of TEDP](image)

**Synonyms:** Dithion\(^®\); Bladafum\(^®\); Sulfotep; Tetraethyl dithiopyrophosphate; Thiotepp\(^®\)

**Uses:** TEDP is a restricted-use organophosphate compound approved only for use as an insecticide within commercial greenhouses [US EPA 1999].

1.2 Purpose

This skin notation profile presents (1) a brief summary of epidemiological and toxicological data associated with skin contact with TEDP and (2) the rationale behind the hazard-specific skin notation (SK) assignment for TEDP. The SK assignment is based on the scientific rationale and logic outlined in the *Current Intelligence Bulletin (CIB) 61: A Strategy for Assigning New NIOSH Skin Notations* [NIOSH 2009]. The summarized information and health hazard assessment are limited to an evaluation of the potential health effects of dermal exposure to TEDP. A literature search was conducted through October 2014 to identify information on TEDP, including but not limited to data relating to its toxicokinetics, acute toxicity, repeated-dose systemic toxicity, carcinogenicity, biological system/function–specific effects (including reproductive and developmental effects and immunotoxicity), irritation, and sensitization. Information was considered from studies of humans, animals, or appropriate modeling systems that are relevant to assessing the effects of dermal exposure to TEDP.

1.3 Overview of SK Assignment

TEDP is potentially capable of causing numerous adverse health effects following skin contact. A critical review of available data has resulted in the following SK assignment for TEDP: **SK: SYS (FATAL)**. Table 1 provides an overview of the critical effects and data used to develop the SK assignment for TEDP.

<table>
<thead>
<tr>
<th>Skin notation</th>
<th>Critical effect</th>
<th>Available data</th>
</tr>
</thead>
<tbody>
<tr>
<td>SK: SYS (FATAL)</td>
<td>Acute toxicity; cholinesterase (ChE) inhibition</td>
<td>Limited animal data</td>
</tr>
</tbody>
</table>
2 Systemic Toxicity from Skin Exposure (SK: SYS)

No toxicokinetic studies of humans or animals were identified that estimated the degree of TEDP absorption through the skin following dermal exposure. The potential of TEDP to pose a skin absorption hazard was evaluated, with use of a predictive algorithm for estimating and evaluating the health hazards of dermal exposure to substances [NIOSH 2009]. The evaluation method compares an estimated dose accumulated in the body from skin absorption and an estimated dose from respiratory absorption associated with a reference occupational exposure limit. On the basis of this algorithm, a ratio of the skin dose to the inhalation dose (SI ratio) of 0.43 was calculated for TEDP. An SI ratio of ≥0.1 indicates that skin absorption may significantly contribute to the overall body burden of a substance [NIOSH 2009]; therefore, TEDP is considered to be absorbed through the skin following dermal exposure. Additional information on the SI ratio and on the variables used in its calculation is included in the appendix.

No estimate of the human dermal lethal dose (LD$_{50}$) was identified for TEDP. Dermal LD$_{50}$ values (lethal doses in 50% of exposed animals) ranged from 65 milligrams per kilogram (mg/kg) for male rats exposed for 7 days to 262 mg/kg for male rats exposed for 4 hours (hr) [Kimmerle and Klimmer 1974], and 0.069 milliliters per kilogram (mL/kg) [corresponding to 82 mg/kg] in rats [Scientific Associates 1950]. The weight of evidence indicates that the acute dermal LD$_{50}$ values in animals are lower than the critical dermal LD$_{50}$ value of 200 mg/kg that identifies chemical substances with the potential to be fatal at low doses following acute dermal exposure [NIOSH 2009]. Therefore, TEDP can be absorbed through the skin, is systemically available, and can be fatal following dermal exposure.

No epidemiological studies, case reports, or occupational exposure studies and no repeated-dose, subchronic or chronic toxicity studies in animals were identified that evaluated the potential of TEDP to cause systemic effects following dermal exposure. However, dermal contact with TEDP at low levels used in the acute dermal toxicity studies [Kimmerle and Klimmer 1974] resulted in depression of cholinesterase (ChE) activity in peripheral and central nervous systems. This effect is consistent with the known mode of action of organophosphates, including TEDP. Kimmerle and Klimmer [1974] also reported ChE inhibition following oral and inhalation exposures of short-term or longer-term duration, indicating that the effect is not route specific.

Table 2. Summary of the carcinogenic designations for TEDP by numerous governmental and nongovernmental organizations

<table>
<thead>
<tr>
<th>Organization</th>
<th>Carcinogenic designation</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIOSH [2005]</td>
<td>No designation</td>
</tr>
<tr>
<td>NTP [2014]</td>
<td>No designation</td>
</tr>
<tr>
<td>US EPA [2012]</td>
<td>No designation</td>
</tr>
<tr>
<td>European Parliament [2008]</td>
<td>No GHS designation</td>
</tr>
<tr>
<td>IARC [2012]</td>
<td>No designation</td>
</tr>
<tr>
<td>ACGIH [2005]</td>
<td>A4: Not classifiable as a human carcinogen</td>
</tr>
</tbody>
</table>

ACGIH = American Conference of Governmental Industrial Hygienists; GHS = Globally Harmonized System for Classification and Labelling of Chemicals; IARC = International Agency for Research on Cancer; NIOSH = National Institute for Occupational Safety and Health; NTP = National Toxicology Program; USEPA = United States Environmental Protection Agency.
function–specific effects (including reproductive and developmental effects and immunotoxicity) following dermal exposure to TEDP. No epidemiological studies or animal bioassays were identified that investigated the carcinogenic potential of TEDP following dermal exposure. Table 2 summarizes carcinogenic designations of multiple governmental and nongovernmental organizations for TEDP.

No in vivo or in vitro toxicokinetic data from humans or animals were identified with regard to the potential of TEDP to be dermally absorbed; however, the mathematical model predicted that TEDP is absorbed through the skin. Acute toxicity data from animals [Scientific Associates 1950; Kimmerle and Klimmer 1974] indicate that TEDP is absorbed through the skin, is systemically available, and can be potentially fatal following dermal exposure. Acute dermal toxicity studies, with support from inhalation and oral studies, indicate that TEDP has the potential to cause ChE inhibition following repeated or prolonged dermal exposure [Kimmerle and Klimmer 1974]. Therefore, on the basis of the data for this assessment, TEDP is assigned the SK: SYS (FATAL) notation.

The limited, conflicting data on direct skin effects [Scientific Associates 1950; Kimmerle and Klimmer 1974] do not allow for adequate evaluation of the potential for TEDP to cause skin irritation. Given these data limitations and inconsistencies, TEDP is not assigned the SK: DIR notation.

4 Immune-mediated Responses (SK: SEN)

No occupational exposure studies, diagnostic (human patch) tests, predictive tests in animals (for example, guinea pig maximization tests, Buehler tests, murine local lymph node assays, or mouse ear swelling tests), or any other studies were identified that evaluated the potential of the substance to cause skin sensitization. Therefore, on the basis of the data for this assessment, TEDP is not assigned the SK: SEN notation.

5 Summary

No in vivo or in vitro toxicokinetic data from humans or animals were identified for evaluating the potential of TEDP to be dermally absorbed; however, the mathematical model predicted that TEDP is absorbed through the skin. Acute toxicity data from animals [Scientific Associates 1950; Kimmerle and Klimmer 1974] indicate that TEDP is absorbed through the skin, is systemically available, and can be potentially fatal following dermal exposure. Acute dermal toxicity studies, with support from inhalation and oral studies, indicate that TEDP has the potential to cause ChE inhibition following repeated or prolonged dermal exposure [Kimmerle and Klimmer 1974]. The
limited, conflicting data on direct skin effects [Scientific Associates 1950; Kimmerle and Klimmer 1974] do not allow for adequate evaluation of the potential for TEDP to cause skin irritation. No diagnostic (human patch) tests and no predictive tests in animals were identified that investigated the potential of TEDP to cause skin sensitization. Therefore, on the basis of these assessments, TEDP is assigned a composite skin notation of "SK: SYS (FATAL)."

Table 3 summarizes the skin hazard designations for TEDP previously issued by NIOSH and other organizations. The equivalent dermal designation for TEDP, according to the Globally Harmonized System (GHS) for the Classification and Labelling of Chemicals, is Acute Toxicity Category 1 (Hazard statement: Fatal in contact with the skin) [European Parliament 2008].

### References

**Note:** Asterisks (*) denote sources cited in text; daggers (†) denote additional resources.


with the U.S. Environmental Protection Agency under TSCA Section 8D. OTS #0545594.


Appendix: Calculation of the SI Ratio for TEDP

This appendix presents an overview of the SI ratio and a summary of the calculation of the SI ratio for TEDP. Although the SI ratio is considered in the determination of a substance’s hazard potential following skin contact, it is intended to serve only as supportive data during the assignment of the NIOSH SK. An in-depth discussion on the rationale and calculation of the SI ratio can be found in Appendix B of the Current Intelligence Bulletin (CIB) 61: A Strategy for Assigning New NIOSH Skin Notations [NIOSH 2009].

Overview

The SI ratio is a predictive algorithm for estimating and evaluating the health hazards of skin exposure to substances. The algorithm is designed to evaluate the potential for a substance to penetrate the skin and induce systemic toxicity [NIOSH 2009]. The goals for incorporating this algorithm into the proposed strategy for assigning SYS notation are as follows:

1. Provide an alternative method to evaluate substances for which no clinical reports or animal toxicity studies exist or for which empirical data are insufficient to determine systemic effects.
2. Use the algorithm evaluation results to determine whether a substance poses a skin absorption hazard and should be labeled with the SYS notation.

The algorithm evaluation includes three steps:

1. determining a skin permeation coefficient \( k_p \) for the substance of interest,
2. estimating substance uptake by the skin and respiratory absorption routes, and
3. evaluating whether the substance poses a skin exposure hazard.

The algorithm is flexible in the data requirement and can operate entirely on the basis of the physicochemical properties of a substance and the relevant exposure parameters. Thus, the algorithm is independent of the need for biologic data. Alternatively, it can function with both the physicochemical properties and the experimentally determined permeation coefficient when such data are available and appropriate for use.

The first step in the evaluation is to determine the \( k_p \) for the substance to describe its transdermal penetration rate [NIOSH 2009]. The \( k_p \), which represents the overall diffusion of the substance through the stratum corneum and into the blood capillaries of the dermis, is estimated from the compound’s molecular weight (MW) and base-10 logarithm of its octanol–water partition coefficient (log \( K_{ow} \)). In this example, \( k_p \) is determined for a substance with use of Equation 1. A self-consistent set of units must be used, such as outlined in Table A1. Other model-based estimates of \( k_p \) may also be used [NIOSH 2009].

**Equation 1: Calculation of Skin Permeation Coefficient \( (k_p) \)**

\[
k_p = \frac{1}{k_{psc} + k_{pol} + k_{aq}}
\]

where \( k_{psc} \) is the permeation coefficient in the lipid fraction of the stratum corneum, \( k_{pol} \) is the coefficient in the protein fraction of the stratum corneum, and \( k_{aq} \) is the coefficient in the watery epidermal layer. These components are individually estimated by

\[
\log k_{psc} = -1.326 + 0.6097 \times \log S_{ow} - 0.1786 \times MW^{0.5}
\]

\[
k_{pol} = 0.0001519 \times MW^{0.5}
\]

\[
k_{aq} = 2.5 \times MW^{0.5}
\]

The second step is to calculate the biologic mass uptake of the substance from skin absorption (skin dose) and inhalation (inhalation dose) during the same period of exposure. The skin dose is calculated as a mathematical product of the \( k_p \), the water solubility \( (S_{ow}) \) of the substance, the exposed skin surface area, and the duration of exposure. Its units are milligrams (mg). Assume that the skin exposure continues for 8
hours to unprotected skin on the palms of both hands (a surface area of 360 square centimeters [cm²]).

**Equation 2: Determination of Skin Dose**

\[ \text{Skin dose} = k_p \times S_w \times \frac{\text{Exposed skin surface area} \times \text{Exposure time}}{360 \text{ cm}^2 \times 8 \text{ hours}} \]

The inhalation dose (in mg) is derived on the basis of the occupational exposure limit (OEL) of the substance—if the OEL is developed to prevent the occurrence of systemic effects rather than sensory/irritant effects or direct effects on the respiratory tract. Assume a continuous exposure of 8 hours, an inhalation volume of 10 cubic meters (m³) inhaled air in 8 hours, and a factor of 75% for retention of the airborne substance in the lungs during respiration (retention factor, or RF).

**Equation 3: Determination of Inhalation Dose**

\[ \text{Inhalation dose} = \frac{\text{OEL} \times \text{Inhalation volume} \times \text{RF}}{10 \text{ m}^3 \times 0.75} \]

The final step is to compare the calculated skin and inhalation doses and to present the result as a ratio of skin dose to inhalation dose (the SI ratio). This ratio quantitatively indicates (1) the significance of dermal absorption as a route of occupational exposure to the substance and (2) the contribution of dermal uptake to systemic toxicity. If a substance has an SI ratio greater than or equal to 0.1, it is considered a skin absorption hazard.

**Calculation**

Table A1 summarizes the data applied in the previously described equations to determine the SI ratio for TEDP. The calculated SI ratio was 0.43. On the basis of these results, TEDP is predicted to represent a skin absorption hazard.

**Appendix References**


Table A1. Summary of data used to calculate the SI ratio for TEDP

<table>
<thead>
<tr>
<th>Variables used in calculation</th>
<th>Units</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Skin permeation coefficient</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Permeation coefficient of stratum corneum lipid path ((k_{psc}))</td>
<td>cm/hr</td>
<td>0.0079</td>
</tr>
<tr>
<td>Permeation coefficient of the protein fraction of the stratum corneum ((k_{pol}))</td>
<td>cm/hr</td>
<td>(8.481 \times 10^{-6})</td>
</tr>
<tr>
<td>Permeation coefficient of the watery epidermal layer ((k_{aq}))</td>
<td>cm/hr</td>
<td>0.1393</td>
</tr>
<tr>
<td>Molecular weight ((MW)^*)</td>
<td>amu</td>
<td>322.32</td>
</tr>
<tr>
<td>Base-10 logarithm of its octanol–water partition coefficient ((Log K_{ow})^*)</td>
<td>None</td>
<td>3.99</td>
</tr>
<tr>
<td>Calculated skin permeation coefficient ((k_p))</td>
<td>cm/hr</td>
<td>0.0075</td>
</tr>
<tr>
<td><strong>Skin dose</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Water solubility ((S_w)^*)</td>
<td>mg/cm³</td>
<td>0.03</td>
</tr>
<tr>
<td>Calculated skin permeation coefficient ((k_p))</td>
<td>cm/hr</td>
<td>0.0075</td>
</tr>
<tr>
<td>Estimated skin surface area (palms of hands)</td>
<td>cm²</td>
<td>360</td>
</tr>
<tr>
<td>Exposure time</td>
<td>hr</td>
<td>8</td>
</tr>
<tr>
<td>Calculated skin dose</td>
<td>mg</td>
<td>0.65</td>
</tr>
<tr>
<td><strong>Inhalation dose</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Occupational exposure limit (OEL)(^†)</td>
<td>mg/m³</td>
<td>0.2</td>
</tr>
<tr>
<td>Inhalation volume</td>
<td>m³</td>
<td>10</td>
</tr>
<tr>
<td>Retention factor (RF)</td>
<td>None</td>
<td>0.75</td>
</tr>
<tr>
<td>Inhalation dose</td>
<td>mg</td>
<td>1.5</td>
</tr>
<tr>
<td><strong>Skin dose–to–inhalation dose (SI) ratio</strong></td>
<td>None</td>
<td>0.434</td>
</tr>
</tbody>
</table>

*Variables identified from SRC [ND].
†The OEL used in calculation of the SI ratio for TEPP was the NIOSH recommended exposure limit (REL) [NIOSH 2005].
This page intentionally left blank.
Delivering on the Nation’s promise: safety and health at work for all people through research and prevention

To receive NIOSH documents or more information about occupational safety and health topics, contact NIOSH at

1–800–CDC–INFO (1–800–232–4636)
TTY: 1–888–232–6348
CDC-INFO: www.cdc.gov/info

or visit the NIOSH website at www.cdc.gov/niosh.
For a monthly update on news at NIOSH, subscribe to NIOSH eNews by visiting www.cdc.gov/niosh/eNews.

DHHS (NIOSH) Publication No. 2015-227

SAFER • HEALTHIER • PEOPLE™